Complete Radiological Response of Metastatic Anaplastic Lymphoma Kinase-Positive Signet Ring Lung Adenocarcinoma to Systemic Chemotherapy Grzegorz Korpanty,

Slides:

Advertisements

Similar presentations

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer Haa-Na Song, MD,

Advertisements

Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor Song Xu, Qingchun Zhao, Sen Wei, Yi.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Hiren J. Mehta, MD, Tan-Lucien Mohammed, MD, Michael A. Jantz, MD

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Invasive Inflammatory Myofibroblastic Tumor of the Lung

ALK FISH and IHC: You Cannot Have One without the Other

Paraneoplastic Opsoclonus-Myoclonus Syndrome as a New and Single Manifestation of Relapsing Disease in a Patient with Small Cell Lung Cancer Ernest Nadal,

Y-L Chang, MD, C-T Wu, MD, Y-C Lee, MD, PhD

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer Haa-Na Song, MD,

Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies

Metastases to Breast from Primary Lung Cancer

Histologic Evolution From Adenocarcinoma to Squamous Cell Carcinoma After Gefitinib Treatment Min-Shu Hsieh, MD, Jie-Yang Jhuang, MD, Syue-Fong Hua,

Resection of Mucinous Lung Adenocarcinoma Presenting with Intractable Bronchorrhea Motoshi Takao, MD, PhD, Takehiro Takagi, MD, Hitoshi Suzuki, MD, PhD,

KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma Taylor M.

How I Do It—Optimal Methodology for Multidirectional Analysis of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples Takahiro Nakajima,

Primary Pulmonary Choriocarcinoma Presenting with a Hemothorax

Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations Lynette M. Sholl, MD, Mizuki Nishino, MD, Saraswati.

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases Jennifer M. Boland, MD, Jin.

Interpretation of Anti-ALK Immunohistochemistry Results

Miliary Mesothelioma: A New Clinical and Radiological Presentation in Mesothelioma Patients with Prolonged Survival After Trimodality Therapy Lesek Purek,

Muhammad Umair Khawar, MD, Bhaskar Bhardwaj, MD, Himanshu Bhardwaj, MD

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer Daniel Morgensztern, MD, Saiama.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Successful Treatment with Crizotinib in Mechanically Ventilated Patients with ALK Positive Non–Small-Cell Lung Cancer Hee Kyung Ahn, MD, Kyeongman Jeon,

Hepatoid Carcinoma of the Lung with Anaplastic Lymphoma Kinase Gene Rearrangement Sean Khozin, MD, Mark J. Roth, MD, Arun Rajan, MD, Karen Smith, MD,

ALK and NRG1 Fusions Coexist in a Patient with Signet Ring Cell Lung Adenocarcinoma Lucia Anna Muscarella, PhD, Domenico Trombetta, PhD, Federico Pio.

A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib Akihiro Tamiya,

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Pulmonary Blastoma with Renal Metastasis Responds to Sorafenib

A Novel EML4-ALK Variant: Exon 6 of EML4 Fused to Exon 19 of ALK

Good Vibrations and the Power of Positron Thinking: Positron Emission Tomography and Endoscopic Ultrasound in Staging of Mesothelioma—Two Case Reports

A New KIT Gene Mutation in Thymic Cancer and a Promising Response to Imatinib Sung Hee Lim, MD, Ji-Yun Lee, MD, Jong-Mu Sun, MD, PhD, Kyoung-Mee Kim,

Ritbune Prakobkit, MD, William Churk-Nam Auyeung, MD

Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Lymph Node Staging in Patients with Non-small Cell Lung Cancer in Nonoperable Patients.

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib Shiro Fujita, MD, PhD, Katsuhiro Masago, MD, PhD, Nobuyuki Katakami, MD, PhD,

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon.

Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

Arnaud Uguen, MD, PhD Journal of Thoracic Oncology

A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib Yoon Jin Cha, MD, PhD, Byoung Chul.

Rapid Response to Trastuzumab Emtansine in a Patient with HER2-Driven Lung Cancer Daniela Weiler, MD, Joachim Diebold, MD, Klaus Strobel, MD, Stefan.

PET/CT Findings for Bone Marrow Carcinosis Because of Lung Adenocarcinoma Keisuke Watanabe, MD, Masaharu Shinkai, MD, PhD, Kenjiro Nagai, MD, Nobuhiro.

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Daniel B. Costa, MD, PhD, Susumu Kobayashi, MD, PhD

Erlotinib in Metastatic Bronchopulmonary Mucoepidermoid Carcinoma

Nivolumab-Induced Granulomatous Inflammation of the Pleura

A Case of Pemetrexed-Induced Acute Lung Injury in Non-small Cell Lung Cancer Hye Ok Kim, MD, Sung Yong Lee, MD, PhD, Jae Jeong Shim, MD, PhD, Kyung Ho.

Anu Dham, MD, Alexander M. Truskinovsky, MD, Arkadiusz Z

Nicholas W. Choong, MD, Robert S. Hellman, MD

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas Jun Fan, MD Journal of Thoracic.

Beware of Underlying Malignancy: Acquired Ichthyosis

Metastatic Lung Cancer to the Pancreas

Collaterals Journal of Thoracic Oncology

Intrathoracic Desmoid Tumor: Brief Report and Review of Literature

Mediastinal Sarcoma with Deviated Tracheal Anatomy

Bronchoesophageal Fistula in a Patient With Stage IIIB Non–Small-Cell Lung Cancer Grzegorz Korpanty, MD, PhD, Scheryll Alken, MD, Lillian Smyth, MD, John.

An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and.

Successful Treatment with Pemetrexed in a Patient with Mucinous Bronchioloalveolar Carcinoma: Long-Term Response Duration with Mild Toxicity Chiyuki.

Nodal Recurrence of Pulmonary Carcinoid 30 Years After Primary Resection Abdel-Mohsen Hamad, MD, Giovanna Rizzardi, MD, Giuseppe Marulli, MD, Federico.

A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient with IHC- Positive and FISH-Negative ALK Jong-Mu Sun, MD, PhD, Yoon-La Choi,

Patterns-of-Care for Thoracic Stereotactic Body Radiotherapy among Practicing Radiation Oncologists in the United States Megan E. Daly, MD, Julian R.

ALK Status Testing in Non–Small-Cell Lung Carcinoma by FISH on ThinPrep Slides with Cytology Material Eugen C. Minca, MD, PhD, Christopher P. Lanigan,

Presentation transcript:

Complete Radiological Response of Metastatic Anaplastic Lymphoma Kinase-Positive Signet Ring Lung Adenocarcinoma to Systemic Chemotherapy Grzegorz Korpanty, MD, PhD, Niall Mulligan, MD, Desmond N. Carney, MD, PhD Journal of Thoracic Oncology Volume 6, Issue 5, Pages 963-965 (May 2011) DOI: 10.1097/JTO.0b013e318215a242 Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Chest x-ray examination at presentation (A, anteroposterior [AP] view; B, right lateral view) showed bulky right-sided hilar mass, consolidation in the right lower lung zone with ipsilateral pleural effusion. Journal of Thoracic Oncology 2011 6, 963-965DOI: (10.1097/JTO.0b013e318215a242) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Bronchioalveolar lavage (BAL) sample cytology showed malignant cells with signet ring features (A). Transbronchial biopsy of right hilar mass was consistent with signet ring adenocarcinoma (B; insert, ×200 magnification; hematoxylin and eosin [HE] staining) that was positive on immunohistochemistry for lung cancer-specific marker, TTF-1 (3+) (C). anaplastic lymphoma kinase (ALK) protein expression (2+) was confirmed by immunohistochemistry (D). Journal of Thoracic Oncology 2011 6, 963-965DOI: (10.1097/JTO.0b013e318215a242) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Whole body positron emission tomography (PET)/computed tomography (CT) scan post four cycles of systemic chemotherapy with carboplatin and pemetrexed showed remarkable radiological response within the right hilar and mediastinal lymphadenopathy (A, F), right lung base tumor (B, G), liver mass (C, D, H, and I), and retroperitoneal lymphadenopathy on the right (E, J). Journal of Thoracic Oncology 2011 6, 963-965DOI: (10.1097/JTO.0b013e318215a242) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions